ACTRN12614001311640
Active, not recruiting
未知
A Phase III randomised, controlled trial to evaluate the effect of exercise during chemotherapy on progression-free survival and physical well-being in patients commencing first line treatment for ovarian cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- niversity of Sydney
- Enrollment
- 524
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer of any histological type, suitable for first\-line chemotherapy
- •2\.Age \> or \= 18 years
- •3\.ECOG status 0\-2
- •4\.Willing and able to comply with all study requirements, including the exercise intervention, timing and/or nature of required assessments
- •5\.Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements
- •6\.Scheduled for chemotherapy or has commenced chemotherapy. Participants must be enrolled prior to commencement of the 2nd cycle of chemotherapy
- •7\.Signed written informed consent
Exclusion Criteria
- •1\.Women with diagnosis of recurrent ovarian cancer
- •2\.History of another malignancy within 3 years prior to registration. Patients with a past history of adequately treated carcinoma\-in\-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, Stage I melanoma in situ or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease\-free for at least 3 years after definitive primary treatment.
- •3\.Concurrent illness, including severe infection or unstable angina that may jeopardise the ability of the patient to undergo the exercise intervention outlined in this protocol with reasonable safety.
- •4\.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine and to evaluate the non-inferiority to Prevenar™ in a single blind design, when administered as a 3-dose primary immunization course before 6 months of age. - 10PN-PD-DIT-001EUCTR2005-003300-11-FIGlaxoSmithKline Biologicals1,600
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-FRAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DKAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DEAGO Research GmbH900
Active, not recruiting
Phase 1
The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) TrialEpithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IVMedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-FIJohanna Mäenpää796